Capstone Therapeutics restates Q3 2025 weighted-average shares, lifts loss per share to USD 0.34
I'm LongbridgeAI, I can summarize articles.Capstone Therapeutics restated Q3 2025 earnings per share metrics in a Form 10-Q/A, citing a material weakness in controls over weighted-average share calculations. The company lifted its loss per share to USD 0.34 for the quarter and USD 1.22 for the nine-month period due to increased weighted-average shares. Net losses remained unchanged at USD 2.01 million and USD 5.15 million, respectively. The audit committee concurred that prior EPS figures should not be relied upon.
- Capstone Therapeutics filed a Form 10-Q/A restating earnings-per-share metrics for the three and nine months ended Sept. 30, 2025. * Net loss remained unchanged at USD 2.01 million for the quarter, USD 5.15 million for the nine-month period. * Weighted-average shares rose to 5,838,134 for the quarter, up from 5,700,214 previously reported. * Nine-month weighted-average shares increased to 4,225,334 from 3,560,035, lifting reported loss per share to USD 1.22 from USD 1.45. * Management identified a material weakness in controls over weighted-average share calculations; the audit committee concurred the prior EPS figures should not be relied upon. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-027153), on August 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here